Literature DB >> 8202653

Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials.

S Senn.   

Abstract

Mesh：

Year:  1994        PMID： 8202653     DOI： 10.1002/sim.4780130310

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  11 in total

Review 1.  The relation between treatment benefit and underlying risk in meta-analysis.

Authors:  S J Sharp; S G Thompson; D G Altman
Journal:  BMJ       Date:  1996-09-21

2.  Relation between treatment benefit and underlying risk in meta-analysis. Standard of "label invariance" should not be abandoned.

Authors:  S Senn
Journal:  BMJ       Date:  1996-12-14

Review 3.  Why sources of heterogeneity in meta-analysis should be investigated.

Authors:  S G Thompson
Journal:  BMJ       Date:  1994-11-19

4.  Statins for primary prevention: at what coronary risk is safety assured?

Authors:  P R Jackson; E J Wallis; I U Haq; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

5.  Controversy and Debate: Questionable utility of the relative risk in clinical research: Paper 2: Is the Odds Ratio "portable" in meta-analysis? Time to consider bivariate generalized linear mixed model.

Authors:  Mengli Xiao; Yong Chen; Stephen R Cole; Richard F MacLehose; David B Richardson; Haitao Chu
Journal:  J Clin Epidemiol       Date:  2021-08-09       Impact factor: 6.437

6.  Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study.

Authors:  Michael Geissbühler; Cesar A Hincapié; Peter Jüni; Bruno R da Costa; Soheila Aghlmandi; Marcel Zwahlen
Journal:  BMC Med Res Methodol       Date:  2021-06-15       Impact factor: 4.615

Review 7.  Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy.

Authors:  Nanna B Finnerup; Simon Haroutounian; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpaa; Troels S Jensen; Peter R Kamerman; Ewan McNicol; Andrew Moore; Srinivasa N Raja; Niels T Andersen; Emily S Sena; Blair H Smith; Andrew S C Rice; Nadine Attal
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

Review 8.  The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.

Authors:  Puvan Tharmanathan; Melanie Calvert; John Hampton; Nick Freemantle
Journal:  BMC Med Res Methodol       Date:  2008-03-20       Impact factor: 4.615

9.  Factors explaining the heterogeneity of effects of patient decision aids on knowledge of outcome probabilities: a systematic review sub-analysis.

Authors:  Stephen J Gentles; Dawn Stacey; Carol Bennett; Mohamad Alshurafa; Stephen D Walter
Journal:  Syst Rev       Date:  2013-10-21

10.  John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.

Authors:  Shannon M Smith; Maurizio Fava; Mark P Jensen; Omar B Mbowe; Michael P McDermott; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2020-09       Impact factor: 7.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.